Contents
On this page
- Interdependence of three material decisions
- Requirements of ICH Q8(R2)
- The active ingredient: priority of solid form selection
- Excipients: function, interaction and variability
- Scope and limitations of the Inactive Ingredient Database
- Populations to which adult precedent does not transfer
- The container closure system as a material decision
- Writing the material justification
- Limitations of the current evidence
- Key points
- Application to your study
- Frequently asked questions
Academy · Research Writing · Drug material selection
Selecting Materials for Drug Development: API Solid Form, Excipients and Container Closure Systems
Three material decisions underpin a drug product: the solid form of the active ingredient, the excipients and the container closure system. ICH Q8(R2) frames all three as questions about what the product must deliver to the patient, reasoned backwards from that objective, rather than as selections from a compendial list. The common failure is to make each decision in isolation and to discover the interactions only during stability testing.
An excipient justification stating that an ingredient is compendial, generally recognised as safe (GRAS) and listed in the Inactive Ingredient Database does not address the questions a reviewer is asking. Those facts establish that the ingredient has precedent. They do not explain why it is included in the formulation, which critical quality attribute it controls, whether it interacts with the active ingredient under the intended storage conditions, or whether the resulting exposure is acceptable in the target population. This article sets out how the three material decisions are connected and how the justification should be written so that the connection is explicit.
Learning objectives
- How ICH Q8(R2) links a quality target product profile to specific material choices through critical quality attributes
- Why the solid form of the active ingredient is the material decision with the widest consequences, and the effect of polymorphism on the remainder of the dossier
- What the Inactive Ingredient Database does and does not establish about an excipient, including why entries were expected to decrease from over 14,000 to about 10,000
- How excipient variability between lots and suppliers affects dosage form performance
- Why paediatric exposure cannot be scaled from adult data, given that body water falls from about 80% at birth to 60% by five months
- The content of a defensible excipient justification paragraph, compared with one that states compendial status alone
Common misconceptions
- “It is in the Inactive Ingredient Database, so it is approved at that level.” The database records maximum potency per dosage unit and maximum daily exposure by route of administration and dosage form in approved products. This constitutes useful precedent, not approval of a specific use at that level in a particular product.
- “Excipients are inert.” At best they are functionally inert, and they are often chemically reactive. Bharate and colleagues, in the Journal of Excipients and Food Chemicals, catalogue interactions and incompatibilities between excipients and active ingredients across a wide range of chemistries; Narang and colleagues set out how those interactions determine solid dosage form stability.
- “Same excipient, same grade, same performance.” Dave and colleagues, in the Journal of Pharmaceutical Sciences, show that excipient variability within specification can change dosage form functionality. A compendial monograph sets identity and purity limits; it does not control the functional properties on which a manufacturing process depends.
- “Quality by design is a documentation style.” ICH Q8(R2) describes it as a systematic approach beginning with predefined objectives, emphasising product and process understanding and process control, based on sound science and quality risk management. A design space developed in this way is proposed by the applicant and assessed by the regulator; it constitutes a regulatory commitment rather than a narrative.
Interdependence of three material decisions
Drug product development involves three material decisions, which are usually made by three groups on three timelines. Chemistry selects the salt, co-crystal or free form of the active ingredient, often during lead optimisation and for reasons of synthesis and bioavailability. Formulation selects the excipients, generally once a dosage form is fixed. Packaging selects the container closure system, often last and under commercial constraints. Each decision is reasonable on its own terms; it is the interactions between them that emerge in accelerated stability studies eighteen months later.
The cost of discovering those interactions late is the principal argument for undertaking this work early. Wouters and colleagues, in JAMA, estimated the median capitalised research and development investment per new medicine at $1,141.7 million across 2009–2018 16. Material decisions are made early in that spend and are expensive to reverse once clinical material has been manufactured against them, because a change to the solid form or to a functional excipient can force bridging work on bioequivalence, stability and sometimes the clinical programme.
This page addresses the pharmaceutical aspect of a paired topic. The device aspect — biocompatibility, ISO 10993 testing and contact categorisation — is a substantially different problem and is treated separately in selecting materials for a medical device. A drug-device combination requires both, together with identification of the component that determines the primary mode of action, because that determines the regulatory route.
The three material decisions and what each one has to be justified against
| Decision | Chosen for | Principal risk if chosen in isolation | Evidence the justification needs |
|---|---|---|---|
| Solid form of the active ingredient salt, co-crystal, polymorph, amorphous | Solubility, dissolution, stability, manufacturability | Form conversion during processing or on storage; bioavailability change after clinical material is made | Complete form screen; characterisation by a method that detects the alternative forms; a control strategy for the selected form |
| Excipients binder, disintegrant, lubricant, solubiliser, stabiliser, preservative | A named function serving a named critical quality attribute | Interaction with the active ingredient; functional variability inside compendial limits | Compatibility screening on the grades to be purchased; internal functional specifications; exposure precedent by route and dosage form, with the population argued |
| Container closure system primary contact materials, closure, device interface | Protection, compatibility, integrity, usability | Leachables into the product, sorption of active or preservative out of it, usability failure in the intended population | Extractables and leachables programme; integrity data for sterile products; usability evidence where the user is part of the delivery |
Structured on the development logic set out in ICH Q8(R2) Pharmaceutical Development, with risks as described by Bharate and colleagues (Journal of Excipients and Food Chemicals), Narang and colleagues, Dave and colleagues (Journal of Pharmaceutical Sciences), Lu and Rohani (Current Medicinal Chemistry) and FDA’s draft guidance on container closure systems.
Requirements of ICH Q8(R2)
ICH Q8(R2) defines quality by design as a systematic approach to development that begins with predefined objectives and emphasises product and process understanding and process control, based on sound science and quality risk management 4. In practice, this entails working from a quality target product profile — dosage form and route, strength, container closure, release characteristics, the attributes relevant to the indicated population — to the critical quality attributes that must be controlled to deliver it, and then to the material attributes and process parameters that determine each one 4,9.
Two aspects of this are commonly misread. First, Q8(R2) is guidance describing an approach; it does not mandate quality by design, and a traditional development package remains acceptable. What a quality-by-design submission adds is a design space, which Q8(R2) frames as the multidimensional combination of material attributes and process parameters shown to assure quality. A design space is proposed by the applicant and assessed by the regulator as part of the application, and movement within an approved design space is not considered a change 4. That is a substantial operational benefit and a substantial evidentiary burden.
Second, Q8(R2) does not stand alone. Quality risk management under ICH Q9 is the mechanism by which the applicant decides which attributes are critical and which parameters require control, and the pharmaceutical quality system described in ICH Q10 maintains the resulting controls over the product lifecycle. A design space without a supporting risk assessment and quality system is a claim rather than a commitment. The Pubrica guide to the ICH guidelines describes how the quality, safety and efficacy series relate to one another.
The active ingredient: priority of solid form selection
The solid form of the active ingredient is the material decision with the widest consequences, because it constrains every downstream decision. Solubility and dissolution rate follow from it, and with them bioavailability and the design of any dissolution specification. Hygroscopicity and chemical stability follow from it, and with them the excipient compatibility profile and the container closure requirement. Mechanical behaviour follows from it, and with it the manufacturability of a tablet.
Polymorphism is the reason this decision is difficult rather than merely consequential. Lu and Rohani, in Current Medicinal Chemistry, and Saifee and colleagues, in the International Journal of Health Research, set out how different crystal forms of the same compound differ in solubility, dissolution, stability and processability, and how forms can convert during processing or on storage 25,26. A form that is stable in the laboratory may not be the thermodynamically stable form, and the thermodynamically stable form may not be the preferred one. Apte, in the International Journal of Pharmaceutical Excipients, makes the related point for salts: the counter ion is a functional choice that changes solubility, hygroscopicity and sometimes compatibility, not a formality 21.
The practical principle is that solid form screening should be complete, and the selected form characterised and controlled by a method capable of detecting the alternatives, before clinical material is manufactured. A form change after pivotal trials is one of the more expensive events in pharmaceutical development. The Pubrica page on the active pharmaceutical ingredient goes into the characterisation detail.
Excipients: function, interaction and variability
An excipient is selected to perform a function: to bind, disintegrate, lubricate, solubilise, stabilise, preserve, mask taste or control release. The justification should begin from that function and the critical quality attribute it serves, because that is the link a reviewer seeks. Milić and colleagues, in Arhiv za farmaciju, discuss how compendial status relates to functionality, and the distinction is critical: a monograph controls identity and purity, while the functional properties on which the process depends — particle size distribution, surface area, degree of substitution, moisture, flow — are often outside its scope 19.
That gap is the source of lot-to-lot and supplier-to-supplier variability. Dave and colleagues, in the Journal of Pharmaceutical Sciences, show how excipient variability within specification translates into changed dosage form functionality 23. The mitigation is not to demand tighter compendial limits, which is not within the applicant’s control; it is to identify the functionally relevant attributes, set internal specifications for them, and qualify suppliers against those specifications rather than against the monograph alone.
Interactions are the second failure mode. Bharate and colleagues review excipient–active incompatibilities comprehensively, and Narang and colleagues examine how those interactions drive solid dosage form stability — Maillard reactions with reducing sugars, acid–base interactions, peroxide-mediated oxidation from polymeric excipients, moisture redistribution 20,24. Early compatibility screening, on the grades actually intended for purchase, is less costly than a stability failure. Awasthi and Banerjee, in RSC Pharmaceutics, illustrate the increasingly common approach of combining in silico prediction with in vitro confirmation for excipient interactions in solid oral dosage design — useful for prioritisation, but not a substitute for the confirmatory work 5.
Co-processed excipients merit separate consideration. Jain and colleagues, in Polymers in Medicine, and Liew and colleagues review their development and use, particularly for fast-disintegrating tablets 8,18. They can resolve a functionality problem effectively; they also create a regulatory one, because a co-processed combination may not have a compendial monograph or an established exposure precedent, and its justification must therefore be constructed rather than cited 10. Our excipient selection page treats this in more detail.
For high-concentration biologics the nature of the material question changes. Jiskoot and colleagues, in the Journal of Pharmaceutical Sciences, and Hu and colleagues, in the AAPS series, set out the challenges of subcutaneous monoclonal antibody formulations, where viscosity, aggregation and injection force are driven by the interaction of protein concentration, buffer, surfactant and excipient choices — and where the container closure and delivery device cannot be selected independently of the formulation 13,15.
Scope and limitations of the Inactive Ingredient Database
The Inactive Ingredient Database is the most frequently cited and most frequently misused resource in excipient justification. It reports, for inactive ingredients in FDA-approved products, the maximum potency per dosage unit and the maximum daily exposure by route of administration and dosage form 3. This is valuable information: it indicates whether the intended use has precedent in an approved product by the same route at a comparable level.
It does not, however, pre-approve the intended use. Precedent at a given level in a given route and dosage form supports an argument that exposure at or below that level is unlikely to raise a new safety question for a comparable population. It is not a finding about the specific product, population or dosing regimen. The distinction matters most where the target population differs from the one in which the precedent was established, as in the paediatric and geriatric cases discussed below.
The database has also been restructured. FDA’s questions-and-answers document on enhancements to the database explained that entries were expected to fall from more than 14,000 to about 10,000 as route of administration and dosage form naming was consolidated — a reduction in redundant entries rather than a withdrawal of precedent 3. The practical consequence is that a justification citing an exposure level should record the route, the dosage form and the date on which the database was consulted, because the record relied upon may be presented differently later. FDA’s more recent generic drug science workshop material on the database programme indicates continued development, so any level cited should be treated as a point-in-time reading and confirmed with the regulatory affairs function before filing 2.
Sources in order: U.S. Food and Drug Administration, Questions and Answers Regarding Enhancements to the Inactive Ingredient Database (CDER); Belayneh A, Tadese E, Molla F, International Journal of General Medicine; Wouters OJ, McKee M, Luyten J, JAMA.
Populations to which adult precedent does not transfer
Excipient exposure is a function of body size and physiology, both of which change rapidly early in life. Belayneh and colleagues, in the International Journal of General Medicine, note that body water falls from about 80% in the newborn to 60% by five months of age, which changes the distribution of water-soluble excipients per kilogram over a period shorter than most development timelines 17. When immature hepatic and renal clearance are also taken into account, an exposure level with well-established adult precedent can be inappropriate in a neonate, sometimes by a wide margin.
Rouaz El Hajoui and colleagues, in Pharmaceutics, review excipients in the paediatric population specifically, and Comoglu and Ozyilmaz, in Pharmaceutical Development and Technology, cover both paediatric and geriatric formulations and the regulatory perspective on them. The recurring finding is that several excipients in routine adult use — certain preservatives, solubilisers and sweeteners among them — carry specific concerns at the paediatric end, and that the evidence base for safe levels in neonates is thinner than for adults 6,12.
The limits of current knowledge should be acknowledged here. Belayneh and colleagues frame part of the problem as off-label use: a substantial share of paediatric prescribing occurs outside the conditions for which any dossier was written, so a considerable proportion of paediatric excipient exposure is never covered by a formal justification 17. In formulation for children, the material decision should be made against paediatric exposure limits where they exist and against an explicit argument where they do not, rather than by scaling an adult value.
The container closure system as a material decision
The container closure system is part of the drug product, and the material questions are of the same kind as for excipients: what it must do, what it can release, and what it can absorb. The relevant considerations are protection from moisture, oxygen and light; compatibility with the formulation; extractables and leachables; sorption of active ingredient or preservative onto the contact surface; and, for sterile products, container closure integrity.
The governing expectation in the United States is changing and should be monitored closely. FDA’s draft guidance Container Closure Systems for Human Drugs and Biological Products is intended to replace the 1999 guidance and its 2002 questions-and-answers companion 1. Because it is a draft, it represents the Agency’s current thinking and is open to comment rather than binding, which places development teams in a difficult position: the superseded guidance is still the published one, while the draft indicates the direction of review expectations. A prudent course is to design the extractables and leachables programme against the draft while confirming the filing position with the regulatory affairs function.
Usability also belongs in this section, because it is a material and design decision with clinical consequences. Carli Lorenzini and Olsson, in the ICED proceedings, examine the gap between pharmaceutical packaging design and the capabilities of elderly users — a problem that is not resolved by selecting a technically adequate barrier material 22. That evidence, and its limitations, are discussed in the role of packaging design in drug development.
Writing the material justification
The justification is where the development work becomes visible or remains invisible. Most excipient justifications that Pubrica is asked to review are lists: name, grade, compendial reference, a one-word function and an Inactive Ingredient Database level. Nothing in such a list connects the excipient to a quality attribute or to a risk, so a reviewer must reconstruct the argument or request it. The stronger version is only slightly longer and is structured as an argument.
An excipient justification, listed versus argued
Lists compendial status
Microcrystalline cellulose (USP-NF) is included as a diluent. It is a widely used, compendial excipient with established safety, is listed in the FDA Inactive Ingredient Database for oral tablets, and is used here within the levels listed in that database. Magnesium stearate (USP-NF) is included as a lubricant on the same basis.
Why is it in the formulation? “Diluent” names a category, not the attribute that it controls.
Which quality attribute does it serve? There is no link to the target product profile, so the reviewer cannot assess criticality.
What controls the functional properties? The monograph controls identity and purity; it does not control particle size or moisture.
Was compatibility tested, on what? Not stated, and “widely used” is not a compatibility argument.
Does the database level transfer to this population? The database level is treated as approval rather than precedent.
Argues from the quality attribute
Microcrystalline cellulose is included as the primary diluent and dry binder because the quality target product profile requires an immediate-release tablet at 12.5 mg strength, which makes content uniformity and disintegration the governing critical quality attributes at this dose. Risk assessment under the quality risk management process identified particle size distribution and moisture content, neither of which is controlled by the USP-NF monograph, as the functionally relevant attributes; internal specifications have therefore been set for both, and suppliers are qualified against those specifications as well as the monograph. Compatibility with the active ingredient was confirmed by binary and full-formulation studies at accelerated conditions on the specific grades to be purchased, with no interaction product detected above the reporting threshold at 6 months. Precedent for oral tablet exposure at this level by this route was confirmed in the FDA Inactive Ingredient Database on the date recorded in Section 3.2.P.4; the intended population is adults, so the adult precedent is applied directly, and no paediatric indication is sought.
The function is tied to a named critical quality attribute, which is tied to the target product profile.
The functionally relevant attributes are identified by risk assessment and controlled internally, beyond the monograph.
Compatibility is evidenced on the purchased grades and the full formulation, with a condition and a duration.
The database is used as dated precedent, with the route and dosage form specified.
The population to which the precedent is applied is stated, so the limit of the argument is visible.
Both paragraphs describe the same formulation and the same testing. The second makes visible the chain from target product profile to quality attribute to material attribute to control, which ICH Q8(R2) expects development to be able to demonstrate. It also defines the boundary of its own argument — adults, this route, this date — which obviates the need for a reviewer to ask.
Limitations of the current evidence
Three gaps should be acknowledged explicitly. First, functional specifications for excipients are not standardised. Milić and colleagues describe the compendial position, but which functional attributes matter for a given formulation remains a product-specific empirical question, and no reference set exists for adoption. Each development programme must therefore address the question anew.
Second, in silico prediction of excipient–active interactions is advancing but is not yet a substitute for experiment. The combined in silico and in vitro approach of Awasthi and Banerjee in RSC Pharmaceutics is representative of good current practice precisely because it retains the confirmatory step. Computational screening should be treated as a prioritisation tool.
Third, paediatric excipient safety limits are incomplete. The reviews by Rouaz El Hajoui and colleagues and by Comoglu and Ozyilmaz converge on the point that for several commonly used excipients the neonatal evidence does not support a confident limit 6,12. Where this applies to a required excipient, the appropriate position in a dossier is to state the gap and present the alternative argument, rather than to cite an adult precedent as though it resolved the question. Where the underlying evidence must be assembled defensibly, that is a systematic review question and should be treated as such.
Key points
Key points
Material selection should proceed backwards from what the product must deliver. ICH Q8(R2) defines quality by design as a systematic approach starting from predefined objectives and emphasising product and process understanding and process control, which establishes the sequence: target product profile, critical quality attributes, and then material attributes and controls. The solid form of the active ingredient is the decision with the widest consequences and should be settled before clinical manufacture. Excipients should be justified by function and tested for compatibility on the grades that will be purchased, with internal specifications for the functional properties that compendial monographs do not control. The Inactive Ingredient Database provides dated precedent by route and dosage form, not approval, and that precedent does not transfer to neonates, in whom body water falls from about 80% at birth to 60% by five months.
Application to your study
Application to your study
- The quality target product profile should be written before any material is shortlisted. It specifies dosage form, route, strength, container closure, release characteristics and the population. Every subsequent material justification should be traceable to an entry in it.
- Critical quality attributes should be listed, with the material attribute that controls each named. An excipient that does not appear against any attribute does not yet have a justification.
- Solid form screening should be completed before clinical manufacture. The analytical method should be confirmed as capable of detecting the forms not in use, not only the selected form.
- The functional excipient attributes on which the process depends should be identified and internal specifications set. These may include particle size, moisture, surface area and degree of substitution, as applicable. Suppliers should be qualified against these attributes as well as against the monograph.
- Compatibility studies should be conducted on the specific grades and suppliers intended for purchase. Both binary and full-formulation studies should be performed at accelerated conditions. Computational screening can prioritise the list but does not replace the study.
- The route, dosage form and date should be recorded for every Inactive Ingredient Database level cited. The database has been restructured and continues to develop; a dated reading is defensible, whereas an undated one is not.
- Where any paediatric use is contemplated, the exposure argument should be based on paediatric limits. Where no limit exists for a required excipient, this should be stated in the dossier together with the alternative argument presented.
- The container closure system should be treated as part of the formulation. Extractables and leachables studies should be designed against the FDA’s current draft guidance on container closure systems, with the filing position confirmed with regulatory affairs, since the draft is not yet binding.
Frequently asked questions
No. ICH Q8(R2) describes quality by design as a systematic approach to development that begins with predefined objectives and emphasises product and process understanding and process control, based on sound science and quality risk management — and it presents it as an approach, not an obligation. A traditional development package remains acceptable. What a quality-by-design submission can gain is a design space: the multidimensional combination of material attributes and process parameters demonstrated to assure quality. A design space is proposed by the applicant and assessed by the regulator, and movement within an approved design space is not considered a change. That operational flexibility requires a substantial evidence base, and it depends on quality risk management under ICH Q9 and a quality system under ICH Q10.
The database indicates that precedent exists, which is not the same as approval. It reports maximum potency per dosage unit and maximum daily exposure by route of administration and dosage form for inactive ingredients in FDA-approved products. That supports an argument that exposure at or below the listed level, by the same route and in a comparable population, is unlikely to raise a new safety question. It does not approve the intended use, and it does not transfer automatically to a different population, route or regimen. The route, dosage form and consultation date should be recorded, because the database has been restructured — entries were expected to fall from over 14,000 to about 10,000 as route and dosage form naming was consolidated.
Because the monograph and functionality are different matters. A compendial monograph controls identity, purity and certain assay limits. The properties on which the process depends — particle size distribution, surface area, moisture content, degree of substitution, flow and compaction behaviour — are frequently outside its scope, so two lots can both comply and still perform differently. Dave and colleagues, in the Journal of Pharmaceutical Sciences, document how that variability propagates into dosage form functionality, and Milić and colleagues, in Arhiv za farmaciju, discuss the relationship between functionality and compendial status. The practical response is to determine which attributes matter for the formulation, set internal specifications, and qualify suppliers against them.
Before clinical material is manufactured for studies on which the applicant intends to rely. Lu and Rohani, in Current Medicinal Chemistry, and Saifee and colleagues explain why: different crystal forms of the same compound differ in solubility, dissolution rate, stability and processability, and forms can convert during processing or on storage. A form change after pivotal clinical work can require bridging bioequivalence data, repeated stability studies and a revised control strategy. The screening should be complete, the selected form characterised, and the analytical method capable of detecting the rejected forms. Salt selection requires the same rigour: the counter ion changes solubility, hygroscopicity and sometimes compatibility.
Not reliably, and least of all in neonates. Belayneh and colleagues, in the International Journal of General Medicine, note that body water falls from about 80% in the newborn to 60% by five months of age, which alters the distribution of water-soluble excipients per kilogram across a few months; hepatic and renal clearance are immature over a similar period. Reviews by Rouaz El Hajoui and colleagues in Pharmaceutics and by Comoglu and Ozyilmaz in Pharmaceutical Development and Technology identify specific excipients of concern in paediatric use and acknowledge that neonatal evidence is often insufficient to set a confident limit. Where this applies to a required excipient, the gap should be stated and the alternative argument presented explicitly.
The position is in transition. FDA has issued a draft guidance, Container Closure Systems for Human Drugs and Biological Products, intended to replace the 1999 guidance and its 2002 questions-and-answers companion. Because it is a draft, it represents the Agency’s current thinking and is open to comment rather than being binding, so the published 1999 document remains the formally issued guidance while the draft indicates the direction of review expectations. A workable approach is to design the extractables, leachables and integrity programme against the draft, since reviewers are likely to apply its expectations, and to confirm the filing position with the regulatory affairs function before submission.
They can resolve a genuine functionality problem — Jain and colleagues, in Polymers in Medicine, and Liew and colleagues review their use particularly in fast-disintegrating tablets, where combining a diluent and a disintegrant in one engineered particle achieves performance that neither achieves in a physical blend. The cost is regulatory. A co-processed combination may have no compendial monograph and no established exposure precedent as a combination, so its justification must be constructed from the properties and precedents of its components together with characterisation of the combination itself. That is a reasonable trade-off when the functionality is genuinely required, and an unnecessary burden when a conventional blend would suffice.
No, and conflating them leads to significant errors. For a device, the governing question is biological evaluation under ISO 10993-1, driven by the nature and duration of body contact, with FDA’s guidance on the use of that standard and the general safety and performance requirements of EU MDR 2017/745 setting the expectations. For a drug product, the governing framework is pharmaceutical development under ICH Q8(R2), with quality risk management under ICH Q9 and the quality system under ICH Q10. They share an analytical toolkit but little else. A drug-device combination requires both, and the component determining the primary mode of action determines the regulatory route — a question for the regulatory affairs function.
References
- U.S. Food and Drug Administration. Container Closure Systems for Human Drugs and Biological Products (draft guidance). U.S. Food and Drug Administration. 2026. read 9 October 2026. packagingdigest.com
- U.S. Food and Drug Administration, CDER Office of Generic Drugs. FDA's Inactive Ingredient Database (IID) Program & AI Consideration. FDA FY2026 Generic Drug Science and Research Initiatives Public Workshop. 2026. read 9 October 2026. fda.gov
- U.S. Food and Drug Administration. Questions and Answers Regarding Enhancements to the Inactive Ingredient Database (IID). U.S. Food and Drug Administration (CDER). 2019. read 9 October 2026. fda.gov
- International Council for Harmonisation; U.S. Food and Drug Administration (CDER/CBER). Guidance for Industry Q8(R2) Pharmaceutical Development. U.S. Department of Health and Human Services, Food and Drug Administration. 2009;Revision 2. read 9 October 2026. fda.gov
- Awasthi G, Banerjee S. Merged in silico-in vitro validations of atenolol and amlodipine besylate with excipient interactions for the design of solid oral dosage forms. RSC Pharmaceutics. 2026. doi:10.1039/D6PM00014B read 9 October 2026. doi.org/10.1039/D6PM00014B
- Comoglu T, Ozyilmaz ED. Pharmaceutical excipients in pediatric and geriatric drug formulations: safety, efficacy, and regulatory perspectives. Pharmaceutical Development and Technology. 2025;30(1):1-9. doi:10.1080/10837450.2024.2441181 read 9 October 2026. doi.org/10.1080/10837450.2024.2441181
- Estape Senti M, Garcia Del Valle L, Schiffelers RM. mRNA delivery systems for cancer immunotherapy: Lipid nanoparticles and beyond. Advanced Drug Delivery Reviews. 2024;206:1-17. doi:10.1016/j.addr.2024.115190 read 9 October 2026. doi.org/10.1016/j.addr.2024.115190
- Jain S, Kaur S, Rathi R, Nagaich U, Singh I. Application of co-processed excipients for developing fast disintegrating tablets: A review. Polymers in Medicine. 2023;53(1):59-68. doi:10.17219/pim/158009 read 9 October 2026. doi.org/10.17219/pim/158009
- Comoglu T, Ozyilmaz ED. Pharmaceutical product development: a "quality by design" (QbD) approach. 2023;1:285-310. doi:10.1016/B978-0-323-91817-6.00001-2 read 9 October 2026. doi.org/10.1016/B978-0-323-91817-6.00001-2
- Liew KB, Hii SH, Helal Uddin ABM, Sarker ZI, Chew YL. Co-processed excipients: a revisit of its development in the past two decades; a review. Journal of Pharmaceutical Negative Results. 2022;13(7):96-103. read 9 October 2026. irep.iium.edu.my
- Zheng X, Zhang P, Fu Z, Meng S, Dai L, Yang H. Applications of nanomaterials in tissue engineering. RSC Advances. 2021;11:19041-19058. doi:10.1039/d1ra01849c read 9 October 2026. doi.org/10.1039/d1ra01849c
- Rouaz El Hajoui K, Chiclana Rodriguez B, Nardi Ricart A, et al. Excipients in the Paediatric Population: A Review. Pharmaceutics. 2021;13(3):387. doi:10.3390/pharmaceutics13030387 read 9 October 2026. doi.org/10.3390/pharmaceutics13030387
- Jiskoot W, Hawe A, Menzen T, Volkin DB, Crommelin DJA. Ongoing challenges to develop high concentration monoclonal antibody-based formulations for subcutaneous administration: Quo Vadis? Journal of Pharmaceutical Sciences. 2021;111(4):861-867. doi:10.1016/j.xphs.2021.11.008 read 9 October 2026. doi.org/10.1016/j.xphs.2021.11.008
- Kumar SSD, Abrahamse H. Advancement of nanobiomaterials to deliver natural compounds for tissue engineering applications. International Journal of Molecular Sciences. 2020;21(18):1-27. doi:10.3390/ijms21186752 read 9 October 2026. doi.org/10.3390/ijms21186752
- Hu Q, Jiang B, Liu D, Tang X, Daly T, Shameem M. Chapter 14: Practical Considerations in High Concentration Formulation Development for Monoclonal Antibody Drug Products. AAPS Advances in the Pharmaceutical Sciences Series. 2020;35:343-372. doi:10.1007/978-3-030-31415-6_14 read 9 October 2026. doi.org/10.1007/978-3-030-31415-6_14
- Wouters OJ, McKee M, Luyten J. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. JAMA. 2020;323(9):844-853. doi:10.1001/jama.2020.1166 read 9 October 2026. doi.org/10.1001/jama.2020.1166
- Belayneh A, Tadese E, Molla F. Safety and Biopharmaceutical Challenges of Excipients in Off-Label Pediatric Formulations. International Journal of General Medicine. 2020;13:1051-1066. doi:10.2147/IJGM.S280330 read 9 October 2026. doi.org/10.2147/IJGM.S280330
- Liew KB, Gaurav A, Mandal UK. A REVIEW ON CO-PROCESSED EXCIPIENTS: CURRENT AND FUTURE TREND OF EXCIPIENT TECHNOLOGY. International Journal of Pharmacy and Pharmaceutical Sciences. 2019;11(1):1-9. doi:10.22159/ijpps.2019v11i1.29265 read 9 October 2026. doi.org/10.22159/ijpps.2019v11i1.29265
- Milic J, Calija B, Krajisnik D. Excipients functionality: Importance and compendial status. Arhiv za farmaciju. 2016;66(2):71-90. doi:10.5937/arhfarm1602071M read 9 October 2026. doi.org/10.5937/arhfarm1602071M
- Bharate SS, Bharate SB, Bajaj AN. Interactions and incompatibilities of pharmaceutical excipients with active pharmaceutical ingredients: a comprehensive review. Journal of Excipients and Food Chemicals. 2016;1(3). read 9 October 2026. doaj.org
- Apte S. The counter ion: expanding excipient functionality. International Journal of Pharmaceutical Excipients. 2016;2(2). doi:10.66617/001c.1126 read 9 October 2026. doi.org/10.66617/001c.1126
- Carli Lorenzini G, Olsson A. DESIGN TOWARDS BETTER LIFE EXPERIENCE: CLOSING THE GAP BETWEEN PHARMACEUTICAL PACKAGING DESIGN AND ELDERLY PEOPLE. DS 80-9 Proceedings of the 20th International Conference on Engineering Design (ICED 15). 2015;9:065-076. read 9 October 2026. designsociety.org
- Dave VS, Saoji SD, Raut NA, Haware RV. Excipient Variability and Its Impact on Dosage Form Functionality. Journal of Pharmaceutical Sciences. 2015;104(3):906-915. doi:10.1002/jps.24299 read 9 October 2026. doi.org/10.1002/jps.24299
- Narang AS, Desai D, Badawy S. Impact of Excipient Interactions on Solid Dosage Form Stability. Excipient Applications in Formulation Design and Drug Delivery. 2015:93-137. doi:10.1007/978-3-319-20206-8_5 read 9 October 2026. doi.org/10.1007/978-3-319-20206-8_5
- M Saifee, N Inamda, D Dhamecha, A Rathi. Drug polymorphism: a review. International Journal of Health Research. 2010;2(4). doi:10.4314/ijhr.v2i4.55423 read 9 October 2026. doi.org/10.4314/ijhr.v2i4.55423
- Lu J, Rohani S. Polymorphism and Crystallization of Active Pharmaceutical Ingredients (APIs). Current Medicinal Chemistry. :884-905. doi:10.2174/092986709787549299 read 9 October 2026. doi.org/10.2174/092986709787549299
Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.
How to cite this article
Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.
Pubrica Academy. (2026, October 9). Selecting Materials for Drug Development: API Solid Form, Excipients and Container Closure Systems. Pubrica. https://pubrica.com/academy/research/selecting-material-for-drug-development/
Pubrica Academy. “Selecting Materials for Drug Development: API Solid Form, Excipients and Container Closure Systems.” Pubrica, 9 Oct. 2026, pubrica.com/academy/research/selecting-material-for-drug-development/.
Pubrica Academy (2026) Selecting Materials for Drug Development: API Solid Form, Excipients and Container Closure Systems. Pubrica. Available at: https://pubrica.com/academy/research/selecting-material-for-drug-development/ (Accessed: 15 October 2026).
Pubrica Academy. “Selecting Materials for Drug Development: API Solid Form, Excipients and Container Closure Systems.” Pubrica. October 9, 2026. https://pubrica.com/academy/research/selecting-material-for-drug-development/
Pubrica Academy, ‘Selecting Materials for Drug Development: API Solid Form, Excipients and Container Closure Systems’ (Pubrica, 9 October 2026) <https://pubrica.com/academy/research/selecting-material-for-drug-development/> accessed 15 October 2026.
Pubrica Academy. Selecting Materials for Drug Development: API Solid Form, Excipients and Container Closure Systems. [Internet]. Pubrica; 2026 Oct 9 [cited 2026 Oct 15]. Available from: https://pubrica.com/academy/research/selecting-material-for-drug-development/
Pubrica Academy, “Selecting Materials for Drug Development: API Solid Form, Excipients and Container Closure Systems,” Pubrica, Oct. 9, 2026. [Online]. Available: https://pubrica.com/academy/research/selecting-material-for-drug-development/
@misc{selecting_material_for_drug_developmen_2026,
author = {{Pubrica Academy}},
title = {Selecting Materials for Drug Development: API Solid Form, Excipients and Container Closure Systems},
howpublished = {Pubrica},
year = {2026},
month = {oct},
url = {https://pubrica.com/academy/research/selecting-material-for-drug-development/},
note = {Accessed: <span data-cite-acc="iso">2026-10-15</span>}
}This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.
Material justification worksheet (one per material)
One copy should be completed for the active ingredient form, one for each excipient and one for the container closure system. The columns represent the argument that a reviewer will otherwise have to reconstruct. Any line answered “widely used” has not yet been answered.
MATERIAL JUSTIFICATION WORKSHEET Product: ______________________ Material: ______________________ Grade / specification: ______________________ Supplier(s): __________________ 1. LINK TO THE PRODUCT Quality target product profile line this serves: ______________________ Critical quality attribute it controls: ______________________ Function in one sentence (not one word): ______________________ 2. WHAT CONTROLS PERFORMANCE Compendial monograph relied on: ______________________ Functional attributes NOT controlled by that monograph: ______________________ Internal specification set for each? [ ] yes [ ] no ref: ______________ Suppliers qualified against internal spec as well as monograph? [ ] yes [ ] no 3. INTERACTION AND STABILITY [ ] Binary compatibility study run, on the purchased grade [ ] Full-formulation study run Conditions and duration: ______________________ Interaction products detected above reporting threshold: ______________________ Computational screening used? [ ] no [ ] yes (triage only; confirmatory study ref: ____) 4. EXPOSURE AND PRECEDENT Route: __________ Dosage form: __________ Level in this product (per unit / per day): ______________________ Inactive Ingredient Database level cited: __________ date consulted: __________ Population the precedent was established in: ______________________ Population this product is for: ______________________ If different, the argument made instead: ______________________ 5. PAEDIATRIC / GERIATRIC SCREEN (complete even if no such indication is sought) [ ] Paediatric indication contemplated now or later? [ ] Paediatric exposure limit exists for this material? limit: __________ [ ] If no limit exists, the gap is stated in the dossier at: __________ 6. CHANGE CONTROL Changes that would reopen this justification: ______________________ Bridging work each would require: ______________________ 7. SIGN-OFF Formulation: __________ Analytical: __________ Toxicology: __________ Regulatory affairs (route, precedent currency, guidance version): __________ Date: __________
Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.
How Pubrica can help
Pubrica’s medical writing and regulatory writing teams develop material justifications that trace from the quality target product profile through the critical quality attribute to the control, so that a reviewer can follow the reasoning without requesting it. Evidence on excipient interactions, variability and population exposure is assembled through documented searches rather than narrative citation, and the pharmaceutical development and container closure sections are written to the structure reviewers expect. Pubrica describes what the guidance requires; the client’s regulatory affairs function determines the filing position.